Case-control study on analgesics and nephropathy (SAN): Protocol

BMC Nephrology

Volumn 6, Issue , 2005, Pages

  Heinemann, Lothar A J ^a   Garbe, Edeltraut ^b   Lewis, Michael ^c   Van Der Woude, Fokko ^d   Graf, Helmut ^e  

^a Berlin Center for Epidemiology and Health Research   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c EPES Epidemiology Pharmacoepidemiology and Systems Research GmbH   (Germany)

^d Klinikum Heidelberg Mannheim   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS PARACETAMOL; AMINOPHENAZONE; ANALGESIC AGENT; DICLOFENAC; DIPYRONE; IBUPROFEN; INDOMETACIN; PARACETAMOL; PARACETAMOL PLUS ACETYLSALICYLIC ACID PLUS CAFFEINE; PARACETAMOL PLUS CAFFEINE; PHENACETIN; PHENYLBUTAZONE; PROPYPHENAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUSTRIA; CLINICAL PROTOCOL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG USE; GERMANY; GROUPS BY AGE; HEALTH CARE ORGANIZATION; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; INFORMATION PROCESSING; INTERVIEW; KIDNEY DISEASE; KIDNEY FAILURE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEMORY; POPULATION RESEARCH; QUALITY CONTROL; QUESTIONNAIRE; RISK FACTOR; SAMPLE; STANDARDIZATION; TECHNICAL AID; TRAINING;

ANALGESICS; AUSTRIA; CASE-CONTROL STUDIES; DRUG COMBINATIONS; GERMANY; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; RESEARCH DESIGN;

EID: 24144448991     PISSN: 14712369     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-6-9     Document Type: Article

References (13)

1. Dubach UC, Levy PS, Minder F: Epidemiological study of analgesic intake and its relationship to urinary tract disorders in Switzerland. Helv Med Acta 1968, 34:297-312.
2. Grimlund K: Phenacetin and renal damage at a Swedish factory. Kungl. Edited by: ktryckeriet Bo. PA. Norstedt & Söner, Stockholm; 1963.
3. Delzell E, Shapiro S: A review of epidemiologic studies of nonnarcotic analgesics and chronic renal disease. Medicine 1998, 77:102-21.
4. McLaughlin JK, Lipworth L, Wong-Ho C, Blot WJ: Analgesic use and chronic renal failure: A critical review of the epidemiologic literature. Kidney International 1998, 54:679-686.
5. Feinstein AR, Heinemann LAJ, Curhan GC, Delzell E, DeSchepper PJ, Fox JM, Graf H, Luft FC, Michielsen P, Mihatsch MJ, Suissa S, Van der Woude F, Willich S, (ad-hoc review committee): The relationship between non-phenacetin combined analegesics and nephropathy: A review. Kidney Internat 2000, 58:2259-2264.
6. Hersh EV, Moore PA, Ross GL: Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther 2000, 22:500-548.
7. Feinstein AR, Heinemann LAJ, Dalessio D, Fox JM, Goldstein J, Haag G, Ladewig D, O'Brien CP: Do Caffeine-containing analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther 2000, 68:457-467.
8. Fox JM, Siebers U: Caffeine as a promotor of analgesic-associated nephropathy - where is the evidence? Fundamental & Clinical Pharmacology 2003, 17:377-92.
9. Greiser E, Molzahn M, eds: Multizentrische Nieren- und Urothel-Carcinom-Studie (Abschlußbericht). Schriftenreihe der Bundesanstalt für Arbeitsschutz und Arbeitsmedizin Fb 780. Wirtschaftsverlag NW, Bremerhaven; 1998.
10. Pommer W, Bronder E, Greiser E, Helmert U, Jesdinsky HJ, et al.: Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989, 9:403-12.
11. McCredie M, Stewart JH, Mahony JF: Is phenacetin responsible for analgesic nephropathy in New South Wales. Clin Nephrol 1982, 17:134-40.
12. Morlans M, LaPorte J, Vidal X, Cabeza D, Stolley PD: End-stage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 1990, 30:717-723.
13. Sandler DP, Smith JC, Weinberg CR, Buckalew VM, Dennis VW, et al.: Analgesic use and chronic renal disease. N Engl J Med 1989, 320:1238-43.